292 related articles for article (PubMed ID: 27925353)
1. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.
Yano K; Seko Y; Takahashi A; Okishio S; Kataoka S; Takemura M; Okuda K; Mizuno N; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Okanoue T; Itoh Y
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32041289
[TBL] [Abstract][Full Text] [Related]
3. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
4. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
Hepatol Res; 2017 Oct; 47(11):1206-1211. PubMed ID: 27917557
[TBL] [Abstract][Full Text] [Related]
5. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
Kim J; Han K; Kim B; Baek KH; Song KH; Kim MK; Kwon HS
Diabetes Res Clin Pract; 2022 Dec; 194():110187. PubMed ID: 36442545
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
[TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Intern Med; 2024 Feb; ():. PubMed ID: 38346734
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
Shikamura M; Takayama A; Takeuchi M; Kawakami K
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38708591
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease.
Choi DH; Jung CH; Mok JO; Kim CH; Kang SK; Kim BY
Endocrinol Metab (Seoul); 2018 Sep; 33(3):387-394. PubMed ID: 30229578
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology.
Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Intern Med; 2020 Aug; 59(16):1931-1937. PubMed ID: 32448832
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
Dwinata M; Putera DD; Hasan I; Raharjo M
Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
[TBL] [Abstract][Full Text] [Related]
17. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Tobita H; Yazaki T; Kataoka M; Kotani S; Oka A; Mishiro T; Oshima N; Kawashima K; Ishimura N; Naora K; Sato S; Ishihara S
J Clin Biochem Nutr; 2021 Mar; 68(2):173-180. PubMed ID: 33879970
[TBL] [Abstract][Full Text] [Related]
19. SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea.
Cho HJ; Lee E; Kim SS; Cheong JY
Sci Rep; 2024 Apr; 14(1):9761. PubMed ID: 38684838
[TBL] [Abstract][Full Text] [Related]
20. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
